 | Up a level |
Al-Bazz, Dalal Y and Wilding, John Ph 
ORCID: 0000-0003-2839-8404
(2020)
Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.
Future Cardiol, 16 (2).
pp. 77-88.
Nicholson, Martha K, Ghazal Asswad, Randa and Wilding, John Ph ORCID: 0000-0003-2839-8404
(2021)
Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.
Expert opinion on pharmacotherapy, 22 (17).
pp. 1-8.
Sprung, Victoria S ORCID: 0000-0002-2666-4986, Kemp, Graham J ORCID: 0000-0002-8324-9666, Wilding, John Ph ORCID: 0000-0003-2839-8404, Adams, Valerie, Murphy, Kieran, Burgess, Malcolm, Emegbo, Stephen, Thomas, Matthew, Needham, Alexander J, Weimken, Andrew et al (show 4 more authors)
(2020)
Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).
BMJ OPEN, 10 (7).
e038856-.
Brown, Emily, Wilton, Moon M ORCID: 0000-0003-4052-7918, Sprung, Victoria S ORCID: 0000-0002-2666-4986, Harrold, Joanne A ORCID: 0000-0002-0899-4586, Halford, Jason CG ORCID: 0000-0003-1629-3189, Stancak, Andrej ORCID: 0000-0003-3323-3305, Burgess, Malcolm, Howarth, Elaine, Umpleby, A Margot, Kemp, Graham J ORCID: 0000-0002-8324-9666 et al (show 2 more authors)
(2021)
A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol.
BMJ open, 11 (7).
e045663-e045663.